Patents by Inventor Raphael Gorodetsky
Raphael Gorodetsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10940241Abstract: Methods are provided for promoting cartilage growth and/or repair. The methods include, administering locally to a site in a subject in need thereof, bone marrow stromal cells attached to fibrin microbeads comprising crosslinked hyaluronic acid and thereby producing stable cartilage locally at the site in the subject.Type: GrantFiled: May 31, 2018Date of Patent: March 9, 2021Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Hadasit Medical Research Services and Development Ltd.Inventors: Pamela Gehron Robey, Sergei Kuznetsov, Raphael Gorodetsky, Astar Hailu-Lazmi, Mitchell Shirvan, Joseph Featherall
-
Publication number: 20200306319Abstract: Methods for treating radiation or chemical injury are described that comprise administering to a subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.Type: ApplicationFiled: June 9, 2020Publication date: October 1, 2020Applicant: PLURISTEM LTD.Inventors: Raphael GORODETSKY, Zami ABERMAN
-
Patent number: 10722541Abstract: Methods for treating radiation or chemical injury are described that comprise administering to a subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.Type: GrantFiled: July 6, 2017Date of Patent: July 28, 2020Assignee: PLURISTEM LTD.Inventors: Zami Aberman, Raphael Gorodetsky
-
Publication number: 20200171215Abstract: Methods are provided for promoting cartilage growth and/or repair. The methods include, administering locally to a site in a subject in need thereof, bone marrow stromal cells attached to fibrin microbeads comprising crosslinked hyaluronic acid and thereby producing stable cartilage locally at the site in the subject.Type: ApplicationFiled: May 31, 2018Publication date: June 4, 2020Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Pamela Gehron Robey, Sergei Kuznetsov, Raphael Gorodetsky, Astar Hailu-Lazmi, Mitchell Shirvan, Joseph Featherall
-
Patent number: 10188741Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.Type: GrantFiled: May 4, 2016Date of Patent: January 29, 2019Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
-
Publication number: 20170368106Abstract: Methods for treating radiation or chemical injury are described that comprise administering to a subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.Type: ApplicationFiled: July 6, 2017Publication date: December 28, 2017Inventors: Zami Aberman, Raphael Gorodetsky
-
Publication number: 20160317675Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.Type: ApplicationFiled: May 4, 2016Publication date: November 3, 2016Inventors: Jacob PITCOVSKI, Ehud SHAHAR, Raphael GORODETSKY
-
Patent number: 9358307Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.Type: GrantFiled: January 25, 2009Date of Patent: June 7, 2016Assignees: GAVISH-GALILEE BIO APPLICATIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
-
Publication number: 20140017209Abstract: Methods for treating radiation or chemical injury are described that comprise administering to a subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.Type: ApplicationFiled: March 22, 2012Publication date: January 16, 2014Applicant: PLURISTEM LTD.Inventors: Zami Aberman, Raphael Gorodetsky
-
Patent number: 8563514Abstract: Provided is a pharmaceutical composition for sequestering cells in connective tissue. The composition includes a biocompatible scaffolding to which one or more peptides or proteins are linked. The peptides or proteins have an amino acid sequence that is a subsequence of human ficolin and are capable of binding the cells to be sequestered. The pharmaceutical composition can be used in the treatment of connective tissue, and can be used as a dermal filler.Type: GrantFiled: August 14, 2008Date of Patent: October 22, 2013Assignee: MetamorefixInventors: Mazal Dahan, Raphael Gorodetsky
-
Patent number: 8354111Abstract: The present invention relates to novel family of homologous cell attachment chimeric peptides. In particular, the present invention relates to chimeric peptides, each comprising synthetic peptides comprising (a) an M-tide comprising an amino acid sequence that is at least 80% homologous to the amino acid sequence selected from the group consisting of: SEQ ID NO:1, 2 and 37; and (b) a core haptide comprising an amino acid sequence homologous to amino acid sequences at the carboxy termini of the and E chains of fibrinogen or other proteins comprising C-termini that are homologous to said fibrinogen sequences, wherein the M-tide and the core haptide originate from the same protein. The synthetic peptides are linked to one another thereby providing the chimeric peptides of the invention which does not occur in the native protein as a continuous sequence. The present invention further discloses pharmaceutical compositions comprising said chimeric peptides and uses thereof.Type: GrantFiled: April 16, 2009Date of Patent: January 15, 2013Assignee: Hadasit Medical Research Services and Development Ltd.Inventor: Raphael Gorodetsky
-
Publication number: 20120207715Abstract: The present invention relates to systems, methods and storage media for preserving and prolonging viability of cultured matrix dependent cells including multipotent progenitor cells, such as mesenchymal stem cells. The system and method of the invention are effective in ambient room temperature and apply during storage and shipment of said cells. The storage medium of the invention comprises fibrin microbeads and culture medium, and is suitable for the maintenance and storage of matrix dependent cells. The methods of the invention comprise use of said system, for attaching matrix dependent cells to fibrin microbeads in culture so as to form cell-fibrin microbead complexes.Type: ApplicationFiled: February 8, 2012Publication date: August 16, 2012Applicant: Hadasit Medical Research Services & Development Ltd.Inventor: Raphael GORODETSKY
-
Publication number: 20120101589Abstract: The present invention relates to methods of coating prosthetic devices with dried fibrin. Particularly, the present invention relates to methods of coating the surface of prosthetic devices with fibrin and drying the fibrin-coated prosthetic devices at moderately-high temperatures for extended periods of time under low atmospheric pressure to obtain prosthetic devices coated with stable cross-linked fibrin capable of binding cells and thereby capable of integrating into tissues.Type: ApplicationFiled: May 12, 2010Publication date: April 26, 2012Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventor: Raphael Gorodetsky
-
Publication number: 20110123629Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.Type: ApplicationFiled: January 25, 2009Publication date: May 26, 2011Applicants: GAVISH-GALILEE BIO APPLIACTIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPEMENT LTD.Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
-
Publication number: 20110111003Abstract: The present invention relates to novel family of homologous cell attachment chimeric peptides. In particular, the present invention relates to chimeric peptides, each comprising synthetic peptides comprising (a) an M-tide comprising an amino acid sequence that is at least 80% homologous to the amino acid sequence selected from the group consisting of: SEQ ID NO:1, 2 and 37; and (b) a core haptide comprising an amino acid sequence homologous to amino acid sequences at the carboxy termini of the and E chains of fibrinogen or other proteins comprising C-termini that are homologous to said fibrinogen sequences, wherein the M-tide and the core haptide originate from the same protein. The synthetic peptides are linked to one another thereby providing the chimeric peptides of the invention which does not occur in the native protein as a continuous sequence. The present invention further discloses pharmaceutical compositions comprising said chimeric peptides and uses thereof.Type: ApplicationFiled: April 16, 2009Publication date: May 12, 2011Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTDInventor: Raphael Gorodetsky
-
Publication number: 20100331254Abstract: Provided is a pulverized fibrin clot and a pharmaceutical composition including a pulverized fibrin clot. The pharmaceutical composition may contain the pulverized fibrin clot suspended in a gel such as cross-linked hyaluronic acid. The pharmaceutical composition may be in a form suitable for injection and may be used, for example, in the treatment of connective tissue, such as skin connective tissue. Also provided is a method for preparing a pulverized fibrin clot as well as a method for treating connective tissue using the pharmaceutical composition.Type: ApplicationFiled: December 25, 2008Publication date: December 30, 2010Applicant: METAMOREFIXInventors: Ascher Shmulewitz, Mazal Dahan, Raphael Gorodetsky
-
Publication number: 20100210544Abstract: Provided is a pharmaceutical composition for sequestering cells in connective tissue. The composition includes a biocompatible scaffolding to which one or more peptides or proteins are linked. The peptides or proteins have an amino acid sequence that is a subsequence of human ficolin and are capable of binding the cells to be sequestered. The pharmaceutical composition can be used in the treatment of connective tissue, and can be used as a dermal filler.Type: ApplicationFiled: August 14, 2008Publication date: August 19, 2010Applicant: METAMOREFIXInventors: Mazal Dahan, Raphael Gorodetsky
-
Publication number: 20090285753Abstract: Novel cell attachment peptides having sequences homologous to specific portions of the carboxy terminal sequence of fibrinogen chains are disclosed. The novel peptides, derived from proteins related to fibrinogen including a peptide adjacent to fibrinogen ?-chain C terminus denoted pre-C? possess cell attraction activities, and are useful in pharmaceutical compositions.Type: ApplicationFiled: May 28, 2009Publication date: November 19, 2009Inventors: Gerard Marx, Raphael Gorodetsky
-
Patent number: 7544655Abstract: Novel cell attachment peptides having sequences homologous to specific portions of the carboxy terminal sequence of fibrinogen chains are disclosed. The novel peptides, derived from proteins related to fibrinogen including a peptide adjacent to fibrinogen ?-chain C terminus denoted pre-C? possess cell attraction activities, and are useful in pharmaceutical compositions.Type: GrantFiled: November 17, 2006Date of Patent: June 9, 2009Assignee: Hadasit Medical Research Services & Development Company Ltd.Inventors: Gerard Marx, Raphael Gorodetsky
-
Publication number: 20070066535Abstract: Novel cell attachment peptides having sequences homologous to specific portions of the carboxy terminal sequence of fibrinogen chains are disclosed. The novel peptides, derived from proteins related to fibrinogen including a peptide adjacent to fibrinogen ?-chain C terminus denoted pre-C? possess cell attraction activities, and are useful in pharmaceutical compositions.Type: ApplicationFiled: November 17, 2006Publication date: March 22, 2007Inventors: Gerard Marx, Raphael Gorodetsky